Share: Facebook Twitter LinkedIn
Activity Provided By:

Physicians’ Education Resource®, LLC.

Optimizing Outcomes in Cold Agglutinin Disease: Exploring the Impact of Rapid Diagnosis and Emerging Therapeutic Agents

Access Activity

Overview / Abstract:

Target Audience

This educational activity is directed toward hematologists and hematologist-oncologists who treat patients with cold agglutinin disease. Fellows, nurses, nurse practitioners, and other health care professionals interested in the management of patients with cold agglutinin disease are also invited to participate.

Activity Overview

Cold agglutinin disease (CAD) has a significant impact on patients’ quality of life. Historically, the limited availability of treatment options has hindered management of CAD. However, the treatment landscape is shifting as novel therapies are developed based on improved understanding of the role of the complement system in the pathogenesis of CAD. Health care professionals require a strong foundation of knowledge in the efficacy, safety, and role of both available and emerging therapies for CAD to improve the outcomes in this patient population.

This program features experts presenting important topics on CAD, including the burden of disease and the impact of CAD on patient quality of life, as well as the role of the complement system in CAD. The program also includes expert review of current and emerging data surrounding strategies for rapid and accurate diagnosis, current management approaches and the potential of emerging treatments.

This educational activity is an archive of the live virtual presentation held on June 10, 2021.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Describe the clinical burden of cold agglutinin disease.
Explain how the complement system is implicated in the onset of cold agglutinin disease.
Apply diagnostic criteria to facilitate an accurate and timely diagnosis of cold agglutinin disease.
Identify complement-mediated therapies for the treatment of cold agglutinin disease based on current and emerging evidence.

Expiration

Jul 14, 2022

Discipline(s)

Physician CME

Format

Online

Credits / Hours

1.5 AMA PRA Category 1 Credit(s)™

Accreditation

ACCME

Presenters / Authors / Faculty

Faculty

FACULTY_NAME
Alexander Röth, MD
Department of Hematology and
Stem Cell Transplantation
West German Cancer Center
University Hospital Essen
University Duisburg-Essen
Essen, Germany

FACULTY_NAME
Sigbjørn Berentsen, MD, PhD
Consultant Hematologist and Senior Researcher
Department of Research and Innovation
Helse Fonna HF, Haugesund Hospital
Haugesund, Norway

FACULTY_NAME
Wilma Barcellini, MD
Director, UOS Physiopathology of Anemias
UO Hematology – Granelli Pavilion
IRCCS Ca’ Granda Foundation
Maggiore Policlinico Hospital
Milan, Italy

FACULTY_NAME
Catherine M. Broome, MD
Associate Professor of Medicine
MedStar Georgetown University Hospital’s Lombardi Comprehensive Cancer Center
Washington, DC

Sponsors / Supporters / Grant Providers

Sanofi Genzyme

Keywords / Search Terms

Relias LLC Relias LLC., FreeCME., Agglutinin Disease Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map